Ideally, RNN would announce their partnership by the end of June. PGNX is up for FDA approval around July 11th, MNKD on July 14th, and INO will release P2 data by the end of July.
No short squeeze, gap up, explosion to $1... as for news, it could come in July or even August. In short, sideways trading till news. Dead money unless you're daytrading.
Those who held on to their shares through the RS will recover any losses plus more if the P2 data is positive. 100% gains for LIQD? Of course when the PPS barely moves 1% on the 1-day, any "gains" are limited. Can't lose what you didn't make.
So you discovered LIQD has no stock options.. good for you, here's a cookie. Options are still a better choice, in theory. CD's are less risky than ETF's, far better price with guaranteed returns. Your return is proportionate to your risk, that's just how investing works. LIQD's "award winning product" nets them approx 2 mill in sales... sounds more like an art gallery than a business. Glad you figured out P2 could fail.. the term here is "double-blind"... the alternative is fudged data, lack of a peer-review process, and the potential for an outbreak of disease. Why comment on efficacy for the HPV Study when the data is yet to be released.. FYI: the data from the P1 study for cervical dysplasia,,was good. No, Roche didn't buy INO... Big Pharma doesn't buy emerging bio's with an unproven platform. The term here is "partnership." INO got a good deal. $10 million upfront, $412.5 mill as milestones are reached. All preclinical and clinical costs paid for by Roche. Roche also takes care of future sales and marketing with INO getting a commission. True, institutional ownership is only 3.63%, but you have enough big names there to keep the ball rolling.... JP Morgan, Credit Suisee, Goldman Sachs, Deutsche Bank, Barclays... the R/S is a good incentive for them to increase their %, while other big names join up. 3 years no... the platform is pretty vast. The possibility of fast-track approval is always on the table. Present INO investors lose little from the R/S... potential new investors will probably have to pay a higher price to get in. Upside, more institutional interest which benefits present investors. No RS for LIQD, you can bet they will dilute first chance they get.
Shorts serve a purpose.. they help increase volatility. Hedgies, via their algorithmic bots, just flip pennies all day. Shorts try to bring the price down, this isn't necessarily bad when you think about it. Hedgies bots prefer sideways trading, doesn't help the shorts in any way. And lastly, shorts don't trade off insider info, you can be sure the bots do.
Followed you on MSTX and ONCS, that's it. LIQD; minimal investment on this end. I doubt you would tread far into my domain; volatility is my specialty: PLUG, NEWL, MOBI, TSLA, etc. Of course INO will be shorted post-PM, every bio is shorted on pops, I was debating whether to short IDIX today. You must mean protracted shorting. A different ballgame there... not to say the outcome isn't in INO's favor... check out what theStreet had to say about IDIX on May 30th. And you're surprised IDRA is posting larger % gains than INO? I could've told you that... back in March when INO was in the 3's and IDRA was gunning in the high 5's... I sold off my INO to daytrade MoMo's, a lucky call when the correction came. IDRA always had the advantage in volume, having observed the daily price action for a while , I would go so far as to say INO's float is carefully controlled. MNKD is an obvious call...that's what you should've been pumping instead of ONCS. Blockbusters of this magnitude deserve extra pimping. Granted, you called out the S3, still. LIQD - they need better clients & sales, long-term.
I said couple hundred million; was a typo, should've read billion. You've gotta do better than that. The R/S isn't a disaster like you swore it would be... INO goes higher and higher... LIQD? Don't tell me that 2 million in sales constitutes a product.
The litigation is probably complicated and could take a while to resolve. On the other hand, if the ruling is in their favor, it could create a buying frenzy with a low PPS and high short interest. So the game isn't over yet.
I don't think they have news. If you had news, you wouldn't sit around while short interest scraped away at shareholder/company value.
Testing new lows each day. Could find the .30's and 40's by week's end. I'm looking forward to it. .30 is the mother of all buying opportunities at minimal cost. Maybe that's what management wants; take it low enough to start a buying frenzy. The combination of OTC and high volume is irresistible. And then send the shuttle into orbit with a solid PR.
Your alter ego missed out on PVCT, PRAN, TRLPF, ADHXF, LPCN, INO, RNN, & IDIX. I pumped a bunch of these days before they spiked. Retail has limited time; who cares if Baker Bro's buy MSTX and it pops in '016. Ask your alter ego to up his game a bit. Just sayin'.
Mensa is beginning to resemble Cramer. Do the opposite and you should be good. Not so sure about the handsome part, but he does give PhD's competition.
Look, I told people here to buy SPEX the day it doubled... if they missed it, I'm not the one who lost out. I only make good calls.YOD, watched it for months, saw the volatility at ~2.50, easy call. I said play the dips, it's up to them to check the chart and buy accordingly. Not forcing anyone to buy.. just giving them the chance to make some extra $$$. You have five senses, limited time, and 100K+ stocks to choose from.
Not here to pump INO. But if someone says LIQD is a better stock, it's worth correcting. You could lose serious $$$ because a pumper told you LIQD is better. Plus, I've done allright with predicting LIQD price action. I said it would go down if the conferences tanked, went down. I said yesterday not to buy in too quickly today, good call or not. I don't give people useless advice, if they bought YOD like I suggested, $$$ today.
FDA approval since 2003, negative earnings since 2003, negative earnings expected throughout '015. Never been approached for a partnership, gee, I wonder why? Also, emerging technologies (immunotherapy) will make chemo/radiation obsolete in 5-10 years. Big Pharma has better options out there.
FDA approval since 2003, negative earnings since that time. 5 years down the road the company will cease to exist when immunotherapy makes radiation/chemo obsolete. Big Pharma has better picks, aka Astra Z and INO.